Stockreport

Alector to Discontinue Phase 2 PROGRESS-AD Trial of Nivisnebart (AL101/GSK4527226) in Early Alzheimer’s Disease Following Interim Futility Analysis

Alector, Inc.  (ALEC) 
Last alector, inc. earnings: 3/24 04:05 pm Check Earnings Report
PDF --Independent data monitoring committee (IDMC) determined the trial unlikely to meet primary endpoint –  --Alector remains focused on advancing its pipeline of novel AB [Read more]